BSE Live
Mar 20, 16:01Prev. Close
113.70
Open Price
113.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:59Prev. Close
114.36
Open Price
116.08
Bid Price (Qty.)
118.22 (2225)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Kopran (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 5.57 | 7.18 | 6.48 | 2.65 | 5.43 | |
| Diluted EPS (Rs.) | 5.57 | 7.18 | 6.48 | 2.65 | 5.43 | |
| Cash EPS (Rs.) | 6.60 | 8.14 | 7.40 | 3.33 | 6.38 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 89.35 | 86.47 | 82.05 | 78.56 | 57.07 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 89.35 | 86.47 | 82.05 | 78.56 | 57.07 | |
| Dividend / Share(Rs.) | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | |
| Revenue from Operations/Share (Rs.) | 56.13 | 70.00 | 56.65 | 42.42 | 51.52 | |
| PBDIT/Share (Rs.) | 9.23 | 11.13 | 9.13 | 4.86 | 9.39 | |
| PBIT/Share (Rs.) | 8.19 | 10.17 | 8.21 | 3.97 | 8.44 | |
| PBT/Share (Rs.) | 7.41 | 9.23 | 7.66 | 3.35 | 7.56 | |
| Net Profit/Share (Rs.) | 5.56 | 7.18 | 6.48 | 2.44 | 5.43 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 16.44 | 15.89 | 16.11 | 11.46 | 18.22 | |
| PBIT Margin (%) | 14.59 | 14.52 | 14.49 | 9.34 | 16.38 | |
| PBT Margin (%) | 13.20 | 13.19 | 13.51 | 7.90 | 14.67 | |
| Net Profit Margin (%) | 9.90 | 10.26 | 11.44 | 5.74 | 10.53 | |
| Return on Networth / Equity (%) | 6.22 | 8.30 | 7.90 | 3.10 | 9.50 | |
| Return on Capital Employed (%) | 8.92 | 11.49 | 9.77 | 4.92 | 14.29 | |
| Return on Assets (%) | 4.91 | 6.77 | 6.17 | 2.53 | 7.24 | |
| Total Debt/Equity (X) | 0.11 | 0.05 | 0.07 | 0.10 | 0.06 | |
| Asset Turnover Ratio (%) | 0.51 | 0.66 | 0.56 | 0.52 | 68.78 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.02 | 2.22 | 1.89 | 1.98 | 1.62 | |
| Quick Ratio (X) | 1.48 | 1.63 | 1.42 | 1.44 | 1.22 | |
| Inventory Turnover Ratio (X) | 5.15 | 6.95 | 6.13 | 3.72 | 8.10 | |
| Dividend Payout Ratio (NP) (%) | 53.85 | 41.75 | 46.27 | 55.24 | 27.63 | |
| Dividend Payout Ratio (CP) (%) | 45.40 | 36.84 | 40.55 | 40.37 | 23.52 | |
| Earnings Retention Ratio (%) | 46.15 | 58.25 | 53.73 | 44.76 | 72.37 | |
| Cash Earnings Retention Ratio (%) | 54.60 | 63.16 | 59.45 | 59.63 | 76.48 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 869.78 | 1,261.05 | 557.78 | 1,391.64 | 466.32 | |
| EV/Net Operating Revenue (X) | 3.21 | 3.74 | 2.04 | 6.80 | 2.09 | |
| EV/EBITDA (X) | 19.52 | 23.51 | 12.68 | 59.37 | 11.48 | |
| MarketCap/Net Operating Revenue (X) | 3.12 | 3.69 | 1.95 | 6.64 | 2.04 | |
| Retention Ratios (%) | 46.14 | 58.24 | 53.72 | 44.75 | 72.36 | |
| Price/BV (X) | 1.96 | 2.99 | 1.35 | 3.58 | 1.84 | |
| Price/Net Operating Revenue | 3.12 | 3.69 | 1.95 | 6.64 | 2.04 | |
| Earnings Yield | 0.03 | 0.03 | 0.06 | 0.01 | 0.05 |
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth